Abstract C36.50H46BrN5O5.50, orthorhombic, P2i2i2i (no. 19) 
Source of material
a-Eigokryptine (5.7 g, 10 mmol) was dissolved in mixture of 50 ml dichloromethane and 50 ml 1,4-dioxane, and 2,2'-azobis(2-methylpropionitrile) (100 mg, Fluka) was added. The solution was stirred at 50 °C (temperature of the bath) and pyrrolidone hydrotribromide (7.44 g, 15 mmol, Aldrich) dissolved in 50 ml dichloromethane and 50 ml 1,4-dioxane was added within about 30 minutes. After 3 hours of stirring at 50 °C, the reaction mixture was diluted with 200 ml dichloromethane and 200 ml of 2 % aqueous solution of sodium carbonate was added. The phases were separated and the organic phase was concentrated obtaining thus 10.3 g of brown oil, containing besides 28 % of 2-bromo-aergokryptine, 56 % and 6 % of two unknown compounds. The oil was dissolved in dichloromethane and chromatographed on a silica gel using dichloromethane as the mobile phase. The fractions, which did not contained 2-bromo-a-ergokryptine, were pooled and evaporated to dryness obtaining thus a yellow solid foam (3.1 g), containing 82.5 % and 8.7 % of two side products. Single crystals of major 2-bromo-l' -α/J-dehydro-ergokryptam (systematic name ^-(2-bromo-D-lysergyl-<^3-dehydrovalyl)-cyc/o(Lleucyl-D-prolyl))were obtained directly by partial evaporation of a saturated solution of its 82.5 % concentrate in acetone (65 mg/ 3 ml) at ambient temperature (298 K).
Experimental details
Two cavities of volumes 595 A 3 are filled with disordered acetone in the unit cell. Since disorder models gave unsatisfactory results, the contribution of the disordered solvent to the scattering factors has been taken into account with PLATON/SQUEEZE [1, 2] . 92 e" were found in each cavity, corresponding to approximately three acetone molecules per cavity. Single crystals of bromokryptam were obtained by chance some time ago and we have succeeded with the crystal structure determination. NMR of one of single crystals dissolved in chloroform-<f3 revealed the presence of acetone, which was considered in the refinement We are well aware that it would be much better to repeat the crystal structure determination at low temperature. Accordingly we tried several times to prepare new crystals, but since that time, crystals of suitable quality have not been obtained. Most probably, high degree of conformation freedom, low stability in solution and limited material available to refine the conditions for crystallization had hampered the formation of a single crystals. Since the substance is rather unusual and serves as well as a proof of yet unknown reaction of ergot alkaloids, we believe that it would be pity to keep it hide-and-seek. 
Discussion
Ergot alkaloids of peptidic type are widely used in the therapy (e.g., bromokryptine mesylate, ergotamine tartrate, dihydroergotamine mesylate, dihydroergotoxine mesylate) and therefore no wonder that considerable effort has been devoted to their degradation products as possible impurities of the used drugs. Crystal structure determination revealed that the compound corresponds in fact to the 2-brominated and 1 '-αβ-dehydro analogue of α-ergokryptam (figure, top) [3, 4] . The 2-bromination of aergokryptine was accompanied by the opening of cyclol ring, dehydration of valine to αβ-dehydrovaline, and finally, by the epimerization of L-proline to D-proline. Apparently, transdiketopiperazine is thermodynamically favored [5] , and thus cisoiketopiptrazint lactam (containing L-proline) is the minor component in the reaction mixture. The ergoline A and Β rings, forming the indole moiety, are nearly planar (χ 2 test values are S.85 and 3.72, respectively). The dihedral angle between these two planes is 1.91 (8) 
